TY - JOUR
T1 - Potential drug-drug interactions in paediatric outpatient prescriptions in Nigeria and implications for the future
AU - Oshikoya, Kazeem Adeola
AU - Oreagba, Ibrahim Adekunle
AU - Godman, Brian
AU - Oguntayo, Fisayo Solomon
AU - Fadare, Joseph
AU - Orubu, Samuel
AU - Massele, Amos
AU - Senbanjo, Idowu Odunayo
N1 - Publisher Copyright:
© 2016 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2016/11/1
Y1 - 2016/11/1
N2 - Background: Information regarding the incidence of drug-drug interactions (DDIs) and adverse drug events (ADEs) among paediatric patients in Nigeria is limited. Methods: Prospective clinical audit among paediatric outpatients in four general hospitals in Nigeria over a 3-month period. Details of ADEs documented in case files was extracted. Results: Among 1233 eligible patients, 208 (16.9%) received prescriptions with at least one potential DDI. Seven drug classes were implicated with antimalarial combination therapies predominating. Exposure mostly to a single potential DDI, commonly involved promethazine, artemether/lumefantrine, ciprofloxacin and artemether/lumefantrine. Exposure mostly to major and serious, and moderate and clinically significant, potential DDIs. Overall exposure similar across all age groups and across genders. A significant association was seen between severity of potential DDIs and age. Only 48 (23.1%) of these patients presented at follow-up clinics with only 15 reporting ADEs. Conclusion: There was exposure to potential DDIs in this population. However, potential DDIs were associated with only a few reported ADEs.
AB - Background: Information regarding the incidence of drug-drug interactions (DDIs) and adverse drug events (ADEs) among paediatric patients in Nigeria is limited. Methods: Prospective clinical audit among paediatric outpatients in four general hospitals in Nigeria over a 3-month period. Details of ADEs documented in case files was extracted. Results: Among 1233 eligible patients, 208 (16.9%) received prescriptions with at least one potential DDI. Seven drug classes were implicated with antimalarial combination therapies predominating. Exposure mostly to a single potential DDI, commonly involved promethazine, artemether/lumefantrine, ciprofloxacin and artemether/lumefantrine. Exposure mostly to major and serious, and moderate and clinically significant, potential DDIs. Overall exposure similar across all age groups and across genders. A significant association was seen between severity of potential DDIs and age. Only 48 (23.1%) of these patients presented at follow-up clinics with only 15 reporting ADEs. Conclusion: There was exposure to potential DDIs in this population. However, potential DDIs were associated with only a few reported ADEs.
KW - Drug: drug interactions
KW - Nigeria
KW - adverse drug events
KW - clinical audit
KW - pediatrics
UR - http://www.scopus.com/inward/record.url?scp=84988381236&partnerID=8YFLogxK
U2 - 10.1080/17512433.2016.1232619
DO - 10.1080/17512433.2016.1232619
M3 - Article
C2 - 27592636
AN - SCOPUS:84988381236
SN - 1751-2433
VL - 9
SP - 1505
EP - 1515
JO - Expert Review of Clinical Pharmacology
JF - Expert Review of Clinical Pharmacology
IS - 11
ER -